论文部分内容阅读
目的探讨重组人组织型纤溶酶原激活剂(rt-PA)静脉溶栓联合小剂量阿司匹林治疗急性脑梗死患者的安全性及有效性。方法选取2014年1月至2015年12月抚顺市中心医院收治的80例急性脑梗死患者作为研究对象,按照随机数字表法将其分为观察组与对照组,各40例。观察组患者给予rt-PA进行静脉溶栓同时口服阿司匹林,对照组患者单独使用阿司匹林。比较两组患者治疗后24 h、7 d、14 d美国国立卫生院卒中量表(NIHSS)评分及生活自理能力评定Barthel指数(BI)指数,并统计治疗期间并发症发生情况。结果治疗后24 h、7 d、14 d,观察组患者的NIHSS评分均显著低于对照组,BI指数均显著高于对照组,差异均有统计学意义(均P<0.05);观察组患者治疗期间出现脑出血、再发脑梗、血尿及消化道出血的比例均显著低于对照组,差异均有统计学意义(均P<0.05)。结论使用rt-PA溶栓联合小剂量阿司匹林治疗急性脑梗死,有效率高,安全性可靠。
Objective To investigate the safety and efficacy of intravenous thrombolysis with recombinant human tissue plasminogen activator (rt-PA) in combination with low-dose aspirin in patients with acute cerebral infarction. Methods Eighty patients with acute cerebral infarction who were treated in Fushun Central Hospital from January 2014 to December 2015 were selected as study subjects and divided into observation group and control group according to random number table method, 40 cases in each group. Patients in the observation group received rt-PA for intravenous thrombolysis and oral aspirin, while patients in the control group received aspirin alone. The National Institutes of Health Stroke Scale (NIHSS) score and Barthel index (BI) index were compared between the two groups at 24 h, 7 d and 14 d after treatment, and the incidence of complications during treatment was calculated. Results NIHSS scores in observation group were significantly lower than those in control group at 24 h, 7 d and 14 d after treatment, and BI index were significantly higher than those in control group (all P <0.05). In observation group The proportion of cerebral hemorrhage, recurrent cerebral infarction, hematuria and gastrointestinal bleeding during treatment was significantly lower than that of the control group (all P <0.05). Conclusion rt-PA thrombolysis combined with low-dose aspirin in the treatment of acute cerebral infarction, high efficiency, reliable and reliable.